Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Franklin County Pneumonia Study Group
Abstract
Levofloxacin had excellent activity in vitro against bacteremic isolates of Streptococcus pneumoniae with 495 (99.2%) of 499 isolates being susceptible. A total of 38 (97.4%) of 39 isolates with minimal inhibitory concentrations > or = 0.12 micrograms/ml of penicillin were susceptible to levofloxacin. There was excellent correlation between the disk diffusion and broth microdilution methods for determining susceptibility. Resistant isolates belonged to four different serotypes. There was no increase in proportion of isolates of S. pneumoniae resistant between 1991 and 1994.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Photochemical behavior of levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.